Advertisement

Medical Oncology

, 33:102 | Cite as

Overexpression of long non-coding RNA NR_036575.1 contributes to the proliferation and migration of papillary thyroid cancer

  • Wei Sun
  • Xiabin Lan
  • Zhihong Wang
  • Wenwu Dong
  • Liang He
  • Ting Zhang
  • Hao ZhangEmail author
Original Paper

Abstract

Current evidence suggests that the human genome produces a large number of non-coding RNAs, including microRNAs and long non-coding RNAs (lncRNAs). Generally, lncRNAs are defined as RNA transcripts longer than 200 nucleotides that are not transcribed into proteins. In recent years, lncRNAs have been reported to play oncogenic roles in tumourigenesis. However, minimal research has been performed on the expression and clinicopathological significance of lncRNAs in papillary thyroid cancer (PTC). In the present study, we investigated not only the expression and clinicopathological significance of a novel lncRNA, NR_036575.1, in PTC tissues and adjacent non-cancerous tissues but also its potential function in TPC1 cells. The expression levels of the lncRNA NR_036575.1 in 83 pairs of PTC tissues and adjacent non-cancerous tissues were detected via quantitative real-time polymerase chain reaction. The relationships between the expression levels and clinicopathological characteristics of the lncRNA NR_036575.1 were analysed. In addition, we established two receiver operating characteristic (ROC) curves to assess the diagnostic value of NR_036575.1 expression. Cell Counting Kit-8 and transwell assays were used to assess cell proliferation and migration, respectively. The expression levels of the lncRNA NR_036575.1 were significantly higher in PTC tissues than in adjacent non-cancerous tissues. High NR_036575.1 expression was associated with extrathyroidal extension (ETE) (P = 0.011) and tumour size (P = 0.006). The ROC curves indicated that NR_036575.1 could potentially serve as a biomarker for identifying PTC and related, non-cancerous diseases (sensitivity, 80.7 %; specificity, 88 %), as well as for differentiating between PTC with or without ETE (sensitivity, 57.8 %; specificity, 86.7 %). NR_036575.1 knock-down significantly inhibited the proliferation and migration of TPC1 cells. Our findings are the first to describe lncRNA NR_036575.1 overexpression in PTC. NR_036575.1 expression was associated with both ETE and tumour size. In addition, NR_036575.1 modulation could regulate TPC1 cell proliferation and migration. The results of our study suggest that NR_036575.1 could be applied as a potential biomarker and a novel therapeutic target for PTC patients.

Keywords

Papillary thyroid cancer LncRNA Extrathyroidal extension Tumour size Biomarker 

Notes

Acknowledgments

This work was supported by the Liaoning BaiQianWan Talents Program (No. 2014921033), Natural Science Foundation of Liaoning Province (No. 2015020536), Science and Technology Project of Shenyang City (No. F16-205-1-41), the Liaoning Province PhD Start-up Fund (Nos. 20141042 and 201501008), and the National Natural Science Foundation of China (Nos. 81402208 and 81502319).

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest in relation to the publication of this study. The authors have full control of all of the primary data and agree to allow the journal to review the data if needed.

Ethical standards

Our study was approved by the Ethics Committee of the First Affiliated Hospital of China Medical University, Shenyang, China.

Informed consent

Written informed consent was obtained from all study participants.

References

  1. 1.
    Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115(16):3801–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Davies L, Welch HG. Thyroid cancer survival in the United States: observational data from 1973 to 2005. Arch Otolaryngol Head Neck Surg. 2010;136(5):440–4.CrossRefPubMedGoogle Scholar
  3. 3.
    Wang Z, Zhang H, He L, Dong W, Li J, Shan Z, et al. Association between the expression of four upregulated miRNAs and extrathyroidal invasion in papillary thyroid carcinoma. Onco Targets Ther. 2013;6:281–7.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Nishida T, Nakao K, Hashimoto T. Local control in differentiated thyroid carcinoma with extrathyroidal invasion. Am J Surg. 2000;179(2):86–91.CrossRefPubMedGoogle Scholar
  5. 5.
    McCaffrey TV, Bergstralh EJ, Hay ID. Locally invasive papillary thyroid carcinoma: 1940–1990. Head Neck. 1994;16(2):165–72.CrossRefPubMedGoogle Scholar
  6. 6.
    Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–41.CrossRefPubMedGoogle Scholar
  7. 7.
    Dang Y, Lan F, Ouyang X, Wang K, Lin Y, Yu Y, et al. Expression and clinical significance of long non-coding RNA HNF1A-AS1 in human gastric cancer. World J Surg Oncol. 2015;13:302.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Li Y, Chen W, He F, Tan Z, Zheng J, Wang W, et al. NEAT expression is associated with tumor recurrence and unfavorable prognosis in colorectal cancer. Oncotarget. 2015;6(29):27641–50.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Yu G, Yao W, Gumireddy K, Li A, Wang J, Xiao W, et al. Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression. Mol Cancer Ther. 2014;13(12):3086–97.CrossRefPubMedGoogle Scholar
  10. 10.
    Lan X, Zhang H, Wang Z, Dong W, Sun W, Shao L, et al. Genome-wide analysis of long noncoding RNA expression profile in papillary thyroid carcinoma. Gene. 2015;569(1):109–17.CrossRefPubMedGoogle Scholar
  11. 11.
    Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295(18):2164–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Ark N, Zemo S, Nolen D, Holsinger FC, Weber RS. Management of locally invasive well-differentiated thyroid cancer. Surg Oncol Clin N Am. 2008;17(1):145–55.CrossRefPubMedGoogle Scholar
  13. 13.
    Park YM, Wang SG, Goh JY, Shin DH, Kim IJ, Lee BJ. Intraoperative frozen section for the evaluation of extrathyroidal extension in papillary thyroid cancer. World J Surg. 2015;39(1):187–93.CrossRefPubMedGoogle Scholar
  14. 14.
    Ahn D, Sohn JH, Jeon JH, Jeong JY. Clinical impact of microscopic extrathyroidal extension in patients with papillary thyroid microcarcinoma treated with hemithyroidectomy. J Endocrinol Invest. 2014;37(2):167–73.CrossRefPubMedGoogle Scholar
  15. 15.
    Shin JH, Ha TK, Park HK, Ahn MS, Kim KH, Bae KB, et al. Implication of minimal extrathyroidal extension as a prognostic factor in papillary thyroid carcinoma. Int J Surg. 2013;11(9):944–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Kim WY, Kim HY, Son GS, Bae JW, Lee JB. Clinicopathological, immunohistochemical factors and recurrence associated with extrathyroidal extension in papillary thyroid microcarcinoma. J Cancer Res Ther. 2014;10(1):50–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Radowsky JS, Howard RS, Burch HB, Stojadinovic A. Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome. Thyroid. 2014;24(2):241–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Kwak JY, Kim EK, Youk JH, Kim MJ, Son EJ, Choi SH, et al. Extrathyroid extension of well-differentiated papillary thyroid microcarcinoma on US. Thyroid. 2008;18(6):609–14.CrossRefPubMedGoogle Scholar
  19. 19.
    Choi JS, Kim J, Kwak JY, Kim MJ, Chang HS, Kim EK. Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. AJR Am J Roentgenol. 2009;193(3):871–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Kentwell J, Gundara JS, Sidhu SB. Noncoding RNAs in endocrine malignancy. Oncologist. 2014;19(5):483–91.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer. 2006;13(2):497–508.CrossRefPubMedGoogle Scholar
  22. 22.
    Mazeh H, Mizrahi I, Halle D, Ilyayev N, Stojadinovic A, Trink B, et al. Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid. 2011;21(2):111–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Dong L, Qi P, Xu MD, Ni SJ, Huang D, Xu QH, et al. Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls. Int J Cancer. 2015;137(5):1128–35.CrossRefPubMedGoogle Scholar
  24. 24.
    Tong YS, Wang XW, Zhou XL, Liu ZH, Yang TX, Shi WH, et al. Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma. Mol Cancer. 2015;14:3.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, et al. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014;12:1671–80.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Wei Sun
    • 1
  • Xiabin Lan
    • 1
  • Zhihong Wang
    • 1
  • Wenwu Dong
    • 1
  • Liang He
    • 1
  • Ting Zhang
    • 1
  • Hao Zhang
    • 1
    Email author
  1. 1.Department of Thyroid SurgeryThe First Hospital of China Medical UniversityShenyangChina

Personalised recommendations